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The molecular mechanisms regulating cell prolifera-
tion and development during the life cycle of malaria
parasites remain to be elucidated. The peculiarities of
the cell cycle organization during Plasmodium falcipa-
rum schizogony suggest that the modalities of cell cycle
control in this organism may differ from those in other
eukaryotes. Indeed, existing data concerning Plasmo-
dium cell cycle regulators such as cyclin-dependent ki-
nases reveal structural and functional properties that
are divergent from those of their homologues in other
systems. The work presented here lies in the context of
the exploitation of the recently available P. falciparum
genome sequence toward the characterization of puta-
tive cell cycle regulators. We describe the in silico iden-
tification of three open reading frames encoding pro-
teins with maximal homology to various members of the
cyclin family and demonstrate that the corresponding
polypeptides are expressed in the erythrocytic stages of
the infection. We present evidence that these proteins
possess cyclin activity by demonstrating either their
association with histone H1 kinase activity in parasite
extracts or their ability to activate PfPK5, a P. falcipa-
rum cyclin-dependent kinase homologue, in vitro. Fur-
thermore, we show that RINGO, a protein with no se-
quence homology to cyclins but that is nevertheless a
strong activator of mammalian CDK1/2, is also a strong
activator of PfPK5 in vitro. This raises the possibility
that “cryptic” cell cycle regulators may be found among
the 50% of the open reading frames in the P. falciparum
genome that display no homology to any known proteins.
Four to eight thousand people, most of them children in
sub-Saharan Africa, die every day from malaria. The spread of
drug resistance in Plasmodium falciparum, the parasitic pro-
tozoan responsible for the vast majority of lethal malaria cases,
is a cause for grave concern with respect to disease control and
renders the development of novel chemotherapeutic agents an
urgent task (1). The identification of potential targets is now
greatly facilitated by the availability of genomic data bases (2)
(see www.PlasmoDB.org) resulting from an international effort
that led to the recent publication of the entire P. falciparum
genome sequence (3).
The life cycle of malaria parasites consists of a succession of
developmental stages, some of which are characterized by in-
tense cell proliferation, whereas in others the cell cycle is
arrested. P. falciparum infection of the human host is initiated
by injection of cell cycle-arrested sporozoites into the blood-
stream by an infected Anopheles mosquito. The sporozoites
rapidly gain the liver and invade hepatocytes, where asexual
multiplication (exoerythrocytic schizogony) occurs, leading to
the production of several thousand merozoites. These are re-
leased into the bloodstream and invade erythrocytes, which
become the site of another round of asexual multiplication,
producing 8–24 new merozoites/infected red blood cell. This
phase of the infection (erythrocytic schizogony) is responsible
for malaria pathogenesis. The molecular mechanisms through
which some of the merozoites, upon red blood cell invasion,
arrest their cell cycle and differentiate into male or female
gametocytes instead of initiating a new round of schizogony are
not understood. Ingestion of gametocytes by a mosquito is
required for transmission to the insect vector, in the midgut of
which these cells mature into gametes; for the male gameto-
cytes, this requires sudden release from cell cycle arrest and
three rounds of cell division to produce eight gametes. Fertili-
zation in the mosquito midgut then yields a zygote, the only
diploid stage in the life cycle of the parasite. Meiotic reduction
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occurs in the ookinete, the motile form into which the zygote
rapidly develops. This ookinete crosses the peritrophic mem-
brane and the midgut epithelium and immobilizes at the
epithelium basal lamina. There it undergoes further devel-
opment into an oocyst, a site of intense asexual multiplication
producing several thousand sporozoites, which are cell cycle-
arrested and accumulate in the salivary glands of the mos-
quito, ready to be injected into a vertebrate host during a
subsequent blood meal (see www.malaria.org for more infor-
mation on malaria).
Obviously, the parasite must tightly regulate its cell division
status in response to its environment to complete its life cycle.
The organization of the Plasmodium cell cycle in the different
developmental stages and the molecular mechanisms through
which its progression is controlled are far from being under-
stood (reviewed in Refs. 4 and 5). Erythrocytic schizogony has
received more attention from researchers than other dividing
stages of the life cycle of the parasite, because (i) this process is
responsible for pathogenesis and (ii) it is comparatively easier
to obtain biological material from infected red blood cells cul-
tured in vitro than from other stages. A clear correspondence
between cellular events occurring during Plasmodium schizog-
ony and the G1, S, G2, and M phases of the “classical” cell cycle
has not been established (6). The invading merozoite is pre-
sumably in G1, and DNA synthesis is initiated in the tropho-
zoite 18 h post-invasion. Nuclear divisions ensue in the ab-
sence of cytodieresis, resulting in the formation of a schizont;
nuclei in a given schizont appear to divide asynchronously (7),
which suggests that cell cycle progression is not dictated solely
by fluctuations in the cytoplasmic abundance of cell cycle reg-
ulators. It is not clear whether a strict succession of S phases
and nuclear divisions occurs, or whether segregation of newly
replicated genomes into individual nuclei takes place in a dif-
ferent way. Plasmodial cell multiplication displays other atyp-
ical features, such as the absence of chromosome condensation,
the maintenance of the nuclear membrane (cryptomitosis), and
the presence of intranuclear spindles.
The asynchrony of nuclear division in a given schizont ren-
ders biochemical analysis of cell cycle progression very difficult.
A possible approach to gaining insight into molecular processes
of cell cycle control in Plasmodium is to study the function,
subcellular localization, and other properties of putative regu-
lators such as cyclins and cyclin-dependent protein kinases
(CDKs).1 Several enzymes related to CDKs have been charac-
terized to date in P. falciparum (reviewed in Ref. 8). Two of
these enzymes have been shown to be activated by association
with cyclins: PfPK5, a putative homologue of CDK1 (9) that can
be activated in vitro by a variety of cyclin-related proteins
including mammalian cyclin H and p25, and Pfcyc-1, the only
Plasmodium cyclin characterized so far (10). Hence PfPK5
appears to display promiscuity in its cyclin requirement. An-
other atypical functional feature of PfPK5, which to our knowl-
edge has not been reported for CDKs from other organisms, is
its ability to autophosphorylate in the presence of a cyclin (10).
Pfmrk, a protein kinase with maximal homology to CDK-acti-
vating kinases (CAKs) of the CDK7 family (11), can also be
activated by Pfcyc-1 (12). The genome of P. falciparum en-
codes at least four additional protein kinases related to CDKs
(8), suggesting that additional cyclins are present as well (in
eukaryotes whose genome sequence is known, the number of
cyclins is larger than that of CDK catalytic subunits). PCR-
based approaches have failed in the identification of malarial
cyclins (but not of CDK-related kinases), presumably because
of the low level of conservation of Plasmodium cyclins with
their counterparts in other eukaryotes. Indeed, Pfcyc-1 iden-
tification had to await the in silico search possibilities offered
by the availability of genomic data bases (10).
In this report, we describe three novel P. falciparum open
reading frames (ORFs) identified in the PlasmoDB data base
on the basis of their relatedness to cyclins at the primary
structure level. We demonstrate that these ORFs encode pro-
teins whose abundance fluctuate during schizogony and that
associate with protein kinase activity in parasite extracts, and
we show that one of them is able to activate PfPK5 in vitro.
Furthermore, we demonstrate that PfPK5 can be efficiently
activated by RINGO, a Xenopus protein unrelated to cyclins
but able to activate a subset of mammalian CDKs (13, 14),
pointing to the possibility that cryptic cyclin-like protein may
be present in malaria parasites.
EXPERIMENTAL PROCEDURES
Molecular Cloning and Bacterial Expression
Pfcyc-2—Oligonucleotides were designed for amplification of a
1173-bp region (positions 2956–4129, carrying the cyclin-related se-
quence) from the 6846-bp ORF (gene PFL1330c in PlasmoDB). The
primers contained BamHI (forward primer, GGGGGATCCATGAATG-
GTGGTGATTTGGTG) or SalI (reverse primer, GGGGTCGACAAT-
AGTTGTATCATTTGTGTGGTC) restriction sites (single underline).
After amplification from a P. falciparum cDNA library (kindly provided
by A. Craig) with Taq DNA polymerase (Takara), the PCR product was
digested with BamHI and SalI prior to insertion in the pGEX-4T3
vector (Amersham Biosciences). The pGEX-4T3-Pfcyc-2 plasmid was
electroporated into Escherichia coli BL21, and (for all three ORF dis-
cussed here) the insert was verified by sequencing prior to expression of
the recombinant protein.
Protein expression and purification were performed essentially as
previously described for GST-Pfcyc-1 (10). Briefly, expression was in-
duced for 4 h at 30 °C with 0.3 mM isopropyl--D-galactoside, after the
250-ml culture reached an A600 value of 0.6 in 2 YT medium with 100
g/ml ampicillin. All of the purification steps were performed at 4 °C.
The bacterial pellets were lysed with lysosyme and by sonication in 5 ml
of lysis buffer (phosphate-buffered saline, pH 7.5, 0.1% Triton, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, and ComplexTM mixture
protease inhibitor tablet from Roche Applied Science). The lysates were
cleared by centrifugation (11000 rpm at 4 °C for 30 min), and the
soluble fraction was incubated for 1.5 h at 4 °C under mild agitation
with 0.5 ml of glutathione-agarose resin (Amersham Biosciences). The
slurry was washed in lysis buffer, and the GST-Pfcyc-2 fusion protein
was eluted with elution buffer (30 mM Tris, pH 8.0, 15 mM NaCl, 2
mM glutathione).
Pfcyc-3—The entire ORF (PFE0920c in PlasmoDB) was cloned into
the BamHI and SalI restriction sites of the pMALc2x vector (New
England Biolabs) after amplification from P. falciparum 3D7 genomic
DNA using the following primers (start and stop codons in double
underline): GGGGGATCCATGGATTACGAGGTAGAGGGA (forward)
and GGGGTCGACTTATTTATTTCCATGTTGATC (reverse). E. coli
DH5 cells were transformed with pMALc2x-Pfcyc-3 plasmid by elec-
troporation. Protein expression and purification was as described above
for the GST fusion proteins, except that lysis buffer was 20 mM Tris, pH
7,5, 200 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
and ComplexTM protease inhibitors and that the MBP-Pfcyc3 fusion
protein was eluted from amylose resin (New England Biolabs) with lysis
buffer supplemented with 10 mM maltose.
Pfcyc-4—(gene PF13_0022 in PlasmoDB) was amplified from a cDNA
library and cloned into the BamHI and SalI restriction sites of pGEX-
4T3. Two constructs were made: the first one contained only the first
exon (residues 1–75) as found in a previous version of PlasmoDB and
was obtained by amplification from 3D7 (15) genomic DNA using the
primers GGGGGATCCATGATGAATGACATAGTTTTA (forward) and
GGGGTCGACTTATTTTACGTTAACGTCAAAATC (reverse). The sec-
ond construct contained the entire PF13_0022 ORF (5 exons), which
was obtained by amplification from cDNA using the same forward
primer and ACGCGTCGACCTATATACCTATTTTGTAAAGCTCCAAT-
ATTC (reverse). Recombinant protein expression and purification
were performed as described above for GST-Pfcyc-2. Expression and
1 The abbreviations used are: CDK, cyclin-dependent protein kinase;
CAK, CDK-activating kinase; ORF, open reading frame; GST, glutathi-
one S-transferase; RT, reverse transcription; MBP, maltose-binding
















purifi-cation of MBP-RINGO (ls26 clone) were performed as described
elsewhere (13).
Parasite Extracts and Pull-down Experiments
P. falciparum (3D7) pellets were sonicated in RIPA buffer (30 mM
Tris, pH 8.0, 150 mM NaCl, 20 mM MgCl2, 1 mM EDTA, 1 mM dithio-
threitol, 10 M ATP, 0.5% Triton X-100, 1% Nonidet P-40, 10 mM
-glycerophosphate, 10 mM NaF, 0.1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 mM benzamidine, and ComplexTM
protease inhibitors). The lysates were cleared by centrifugation (15,000
rpm for 15 min at 4 °C), and the total amount of proteins in the
supernatant was measured by a Bio-Rad protein assay. The beads
coated with GST, GST-Pfcyc-1, GST-Pfcyc-2, or GST-Pfcyc-4 were incu-
bated in these parasite extracts or in RIPA buffer alone at 4 °C, under
mild agitation for 90 min (100 g of total parasite proteins for 10 g of
recombinant protein on beads). The beads were then washed three
times in RIPA buffer, once in RIPA buffer with 0.1% SDS, and once in
kinase buffer (25 mM Tris, pH 7.5, 15 mM MgCl2, 2 mM MnCl2, 10 mM
NaF, 10 mM -glycerophosphate). A kinase assay was then performed
by adding 15 M ATP, 5 Ci of [-32P]ATP (3000 Ci/mmol; Amersham
Biosciences), and 5 g of histone H1 in kinase buffer, and the samples
were analyzed by SDS-PAGE and autoradiography.
RT-PCR
Total RNA samples were extracted from asexual cultures of clones
3D7 (15) and F12 (16) and from Percoll purified 3D7 gametocytes
(stages III, IV, and V) using the Qiagen Rneasy® Mini Kit and then
treated with Promega RQ1 RNase-free DNase. RT-PCRs were per-
formed with 100 ng of total RNA using the Invitrogen SuperScriptTM
One-StepTM RT-PCR system with 2 mM MgSO4 and 20 pmol of primers/
reaction, with exception for Pfcyc-1, where 50 pmol of primers, and
TaKaRa Ex Taq Polymerase were utilized. In control reactions reverse
transcriptase was omitted, and only AmpliTaq Polymerase (TaKaRa for
Pfcyc-1) was present. The reactions were incubated at 48 °C for 1 h;
94 °C for 2 min; 30 cycles at 94 °C for 30 s, 5 °C for 1 min, and 68 °C for
2 min; followed by 7 min at 68 °C.
The sequences of oligonucleotides specific for Pfcyc-1, Pfcyc-2, and
Pfcyc-3 are indicated above. Primers specific for genes MSP-1 and
Pfg377 were as follows: MSP-1 dir, 5-GAAGCTTTAGAAGATGCAGT-
ATTGACAGG-3; MSP-1 rev, 5-GATATTTGAGTTCTTTAATAGTGA-
ACAAG-3; Pfg377 dir, 5-TTATCAAACGATGATACTAATGAAAATG-
G-3; and Pfg377 rev, 5-ATATTTAAAATTCGAAAAGTCATAG-
GTAC-3.
Antibodies
The following peptides were obtained from NeoSystems: Pfcyc-1,
residues 312–326, (C)-KEDNVTEPNKKLQVS-COOH; Pfcyc-2, resi-
dues 376–391 of the cloned portion of the ORF, (C)-EIYSEQKYDHT-
NDTTI-C-terminal amide; Pfcyc-3, residues 51–66, SLKNYTERIGKY-
IGCS (C-terminal amide); and Pfcyc-4, residues 1–15, MMNDIVLINK-
KKTPS-(C) (C-terminal amide). The peptides were designed with a
terminal cysteine residue (except for Pcyc-3, whose chosen peptide
contains an internal cysteine) and coupled to rabbit albumin using
3-maleimidobenzoic acid N-hydroxysuccinimide ester (17). Two chick-
ens were immunized intramuscularly in the breast muscle with 200 g
of the peptide (as a conjugate) emulsified with Freund’s complete adju-
vant on day 0 of the experiment and at weeks 2, 4, and 6 with conjugate
emulsified with Freund’s incomplete adjuvant (17). Eggs were collected
and labeled for 16 weeks after immunization and stored at 4 °C until
processed. IgY was isolated from chicken yolks using the method of
Polson et al. (18) involving a series of polyethylene glycol precipita-
tions. The final IgY pellet was resuspended in 0.1 M sodium phos-
phate buffer, pH 7.6, containing 0.02% sodium azide and stored at
4 °C. IgY was isolated from eggs each week. Anti-peptide antibodies
were affinity-purified by cycling the isolated antibodies over a Sul-
foLink-peptide affinity column prepared according to the manufac-
turer’s instructions (Pierce). The antibodies were eluted with glycine
HCl, pH 2.8, and the pH of the eluant was neutralized with 10%
volume of 1 M phosphate buffer at pH 8.5. Protein was measured at
280 nm, and the concentration was determined using the IgY extinc-
tion coefficient of 1.25.
Western Blotting and Immunoprecipitation
P. falciparum 3D7 maintained in a modified erythrocyte culture (19)
were synchronized by 5% sorbitol (20). The parasites were released
from infected erythrocytes by saponin (0.1% w/v) lysis. Cell-free ex-
tracts were prepared by resuspending synchronized parasite pellets
from different developmental stages of growth in M-PER Mammalian
Protein Extraction Reagent, (Pierce) containing a protease inhibitor
mixture (Roche Applied Science). Following 15 min of incubation at
4 °C, the lysate was centrifuged at 12,000  g for 15 min at 4 °C.
Western blot analysis was performed using Supersignal West pico kit
according to the manufacturer’s recommendations, using appropriate
immunopurified primary and secondary antibodies. The relative inten-
sities of the bands were quantified in a Bio-Rad Gel Doc 2000 system
using Quantity One software.
For immunoprecipitation, parasite extract (100 g) was incubated
with immunopurified anti-Pfcyc-1, -Pfcyc-2, -Pfcyc-3, or -Pfcyc-4
chicken antibodies (1.5 g) on ice for 2 h. Protein A-Sepharose CL4B
(Amersham Biosciences) was coated with anti-chicken IgY rabbit anti-
bodies (Pierce) for 90 min under mild agitation at 4 °C in RIPA buffer
and washed four times with RIPA buffer. The immunocomplexes in the
parasite extract were then precipitated with 10 l of protein A/anti-
chicken rabbit antibody beads at 4 °C under mild agitation for 90 min.
The following chicken IgY antibodies were used as negative controls:
nonimmune, immunopurified anti-human C5a receptor (against the
peptide sequence DSKTFTPSTDDTSPRKSQAV) and immunopurified
anti-MIE-2, a Trypanosoma glucose transporter (against the peptide
sequence MIEGSRNSSAVKKRLVAKPLEEC). Another negative con-
trol was performed by omitting the primary IgY altogether and incu-
bating the extract only with anti-chicken/protein A beads. Immunocom-
plexes were washed three times in RIPA buffer, once in RIPA buffer
with 0.1% SDS, and once in kinase buffer and finally suspended in 30 l
of kinase buffer. The kinase assays were performed in a standard
reaction as described below.
Kinase Assays
The assays were performed in a standard reaction (30 l) containing
25 mM Tris-HCl, pH 7.5, 15 mM MgCl2, 2 mM MnCl2 15 M ATP, 5 Ci
of [-32P]ATP (3000 Ci/mmol; Amersham Biosciences) and 5 g of his-
tone H1 (Invitrogen) or 2 g GST-CTD. The reactions were initiated by
addition of 0.5 or 1.0 g each of the recombinant protein kinase and a
cyclin partner, after both proteins had been allowed to form a complex
at 30 °C for 15 min in kinase assay buffer. The kinase reactions
proceeded for 30 min at 30 °C and were stopped by the addition of
Laemmli buffer, boiled for 3 min and analyzed by electrophoresis on
12% SDS-polyacrylamide gel. The gels were dried and submitted to
autoradiography.
RESULTS
In Silico Identification of Three P. falciparum ORFs
Related to Cyclins
We performed BLASTP searches of the PlasmoDB data base
using as queries a variety of cyclin sequences from diverse
organisms and also used the “text search” tool on the Plas-
moDB website, using the word “cyclin” as a query. This enabled
us to identify the previously characterized Pfcyc-1 gene (10), as
well as three additional ORFs, all of which displayed maximal
homology to various cyclins upon BLASTP analysis of general-
ist data bases (Table I).
TABLE I
Characteristics of the cyclin-related proteins included in this study
PlasmoDB identifier Pfam PF00134 score Size(amino acids) Maximal homology Expected molecular mass
kDa
Pfcyc-1 PF14_0605 2.2 327 (1 exon) Cyclin H (20% identity) 39.2
Pfcyc-2 PFL1330c 8 2281 (2 exons) Plant mitotic cyclins (13% identity) 273.5
Pfcyc-3 PFE0920c 3.2 229 (1 exon) T. brucei CYC2 (26% identity) 26.8
Pfcyc-4 PF13_0022 13.4 226 (5 exons) ania-type cyclins (33% identity) 31.1















Pfcyc-2—The first novel ORF we identified in this search is
located on chromosome 12 (gene PFL1330c in PlasmoDB), com-
prises two exons, and potentially encodes a large protein; the Pf
annotation predicts a 2281-residue polypeptide, which includes
a 390-amino acid sequence (residues 986–1376) that meets the
criteria for recognition as a cyclin in the Pfam conserved do-
main data base (Table I). Indeed, performing a BLASTP anal-
ysis using this region as a query to screen generalist data
bases, we found that all of the high score entries were cyclins
from a variety of organisms, most of them mitotic (A and B
type) cyclins. Despite this consistency, the homology is rather
low (13% identity over the 390-residue cyclin-like region with a
cyclin from Asterina pectinifera, increasing to 40% identity over
the most conserved 80 residues within the cyclin box). An
alignment of this region with two of the most closely related
cyclins is shown in Fig. 1A.
To verify that the Pfcyc-2 cyclin-like region was part of a
much larger polypeptide, as predicted by the algorithms in
FIG. 1. Alignments of the deduced amino acid sequences of the malarial cyclins. The cyclin boxes are underlined. A, Pfcyc-2 aligned with
Oryza sativa CYC2B (sptr accession number Q9SSZ5) (42) and cyclin A from the starfish A. pectinifera (P90681). The MRAIL motif cited in the text
is boxed. B, Pfcyc-3 aligned with T. brucei CYC2 (Q9NG22) (21) and Trypanosoma cruzi CYC6 (Q9GQL7) (43). C, Pfcyc-4 aligned with a putative cyclin
from Arabidopsis thaliana (Q94L33) and ania-6a cyclin from Anopheles gambiae (NCBI accession number EAA00916). The position of the frameshift
































PlasmoDB, we performed RT-PCR experiments (data not
shown) with P. falciparum mRNA and primers designed from
the predicted ends of the entire ORF. This enabled us to am-
plify the entire region (2.7 kb) lying 3 to the cyclin-related
sequence. Sequence analysis demonstrated that the 5 bound-
ary of the intron is shorter than that predicted in PlasmoDB; in
our cDNA the intron was located between positions 6170 and
6327 (counting from the initiation codon) instead of positions
6104 and 6327 as predicted in the data base. We were unable to
obtain PCR product starting at the predicted translation initi-
ation site, presumably because of the large size of the mRNA.
However, we obtained a PCR product extending 1.3 kp up-
stream of the cyclin-related region. Taken together, these
experiments demonstrate that the Pfcyc-2 mRNA is at least
5.2 kb in size (from nucleotides 1633 to 6846 in the PlasmoDB
entry). Furthermore, sequence analysis showed that a con-
tinuous ORF embeds the cyclin-related region, as predicted
on PlasmoDB (although we noticed a 1-base deletion in a
stretch of As outside the cyclin region (position 4376), prob-
ably arising from polymerase slippage during reverse tran-
scription; this is a common occurrence with the AT-rich ma-
larial genes).
Pfcyc-3—This single-exon ORF is located on chromosome 5
(gene PFE0920c) and potentially encodes a 229-amino acid
polypeptide. The ORF is flanked on both sides by regions that
are extremely AT-rich, which are characteristic of noncoding
DNA in P. falciparum. The highest score obtained by BLASTP
analysis of the Pfcyc-3 ORF on generalist data bases corre-
sponds to the Trypanosoma brucei CYC2 gene, which was iden-
tified by complementation of a yeast G1 cyclin mutant (21).
Pfcyc-3 shows 26% identity to TbCYC2 over the entire ORF and
44% identity over the most conserved region (residues 40–155;
see Fig. 1B for an alignment). Most other BLASTP high score
entries are cyclin-related proteins.
Pfcyc-4—The last cyclin-related sequence identified in this
search was initially found in PlasmoDB as a 74-amino acid
ORF located on chromosome 13. Subsequent experimental data
from Western blot experiments (see below) suggested that the
ORF should actually be larger, and we therefore re-examined
the latest version of PlasmoDB. Indeed, the Pfcyc-4 ORF had
been updated, and now gene prediction algorithms all predicted
ORFs between 202 and 262 amino acids, the discrepancies
being due to differences in the number and boundaries of pre-
dicted introns. RT-PCR using primers designed to discriminate
between the three models, followed by sequence analysis of the
amplicons, allowed us to establish the validity of the 5-exon Pf
annotation prediction (gene PF13_0022). The 262-residue, 31-
kDa polypeptide potentially encoded by the Pfcyc-4 ORF is
recognized as a cyclin by the SMART conserved domain data
base (entry: smart00385.5) and contains two cyclin boxes, like
the recently described ania-6-type cyclins (22), to which it ap-
pears to be related. Interestingly, the highest BLASTP scores
for the entire Pfcyc-4 ORF correspond to uncharacterized ania-
like cyclins from insects (33% identity with an Anopheles cy-
clin), followed by ania cyclins from plants and mammals (see
Fig. 1C for an alignment). Surprisingly, all amplicons obtained
from several independent RT-PCR experiments had a frame-
shift mutation (deletion of one base in a stretch of 7 As) at
position 565, resulting in a predicted polypeptide containing
one cyclin box instead of two (see Fig. 1C). As will be shown
below, the N-terminal part of the protein is sufficient to display
protein-kinase binding properties.
Expression of the Cyclin-related Genes in
Erythrocytic Stages
mRNAs—To determine whether the newly found genes are
expressed during erythrocytic infection, we performed RT-PCR
experiments on total RNA from in vitro cultures of two clones,
the reference clone 3D7 (15) and its gametocyteless derivative
F12 (16), and from Percoll purified 3D7 gametocytes (Fig. 2).
RT-PCRs specific for the genes MSP-1, encoding the merozoite-
specific surface antigen 1 (23), and pfg377, encoding the game-
tocyte-specific protein Pfg377 (24), were used to characterize
the RNA samples prior to cyclin expression analysis. The msp-
1-specific band indicated, as expected, the presence of schizont
RNA in both asexual cultures of 3D7 and F12 and detected the
unavoidable schizont contamination (4% by morphological
examination) in the sample of Percoll-purified gametocytes.
The pfg377 specific band, readily detectable in RT-PCR from
gametocyte RNA, was detectable at a much lower level also in
the 3D7 asexual RNA, diagnostic of the presence of a minor
gametocyte fraction. No pfg377 amplification band was present
in RT-PCR from RNA from F12, a gametocyteless clone. RT-
PCR of Pfcyc-2 and Pfcyc-3 yielded strong signals both from
RNA from asexual stages and from gametocytes. In contrast,
the Pfcyc-1 amplification product was much more abundant
when gametocyte RNA was used than in the asexual samples,
suggesting that this gene may be developmentally regulated
and predominantly expressed in sexual stages (although Pf-
cyc-1 protein is readily detected in asexual parasite protein
extracts; see below). In all cases, negative controls in which
reverse transcriptase had been omitted gave no signal, allow-
ing us to exclude the possibility that amplification bands de-
rived from contaminating genomic DNA. At the time we per-
formed this series of RT-PCR experiments, Pfcyc-4-specific
FIG. 2. RT-PCR analysis of Pfcyc-1 (lanes 7–12), Pfcyc-2 (lanes 13–18), and Pfcyc-3 (lanes 19–24) using RNA from gametocytes (gam)
or asynchronous asexual stages (as) from P. falciparum clones 3D7 or F12. The plus and minus signs indicate RT-PCRs performed
in the presence or absence of reverse transcriptase, respectively. The controls to the left concern RT-PCR with primers to the following
genes. Lanes 1, 3, and 5, msp-1; lanes 2, 4, and 6, pfg377. The right panel shows Pfcyc-4 PCR products obtained from a cDNA library from asexual
















oligonucleotides were not available. We were however able to
demonstrate that an amplification product corresponding to
the spliced transcript was readily obtained from a blood stages
cDNA library, suggesting that the gene is expressed in these
stages (Fig. 2). This was confirmed by Western blot analysis
(see below).
Proteins—We next obtained peptide-derived antibodies
against the polypeptides encoded by the four cyclin-related
genes. The antibodies against peptides derived from Pfcyc-1,
Pfcyc-2, and Pfcyc-4 recognized their cognate recombinant pro-
tein and showed no cross-reactivity with noncognate cyclin-like
proteins (Fig. 3A). Antibodies directed against Pfcyc-3 failed to
produce a signal on Western blots (but see below for immuno-
precipitation results). Western blot analysis of synchronized
parasites (Fig. 3, B and C) confirmed that Pfcyc-1, Pfcyc-2, and
Pfcyc-4 are expressed in asexual intraerythrocytic parasites
and indicated that the abundance of all three gene products
fluctuates during progression of the schizogonic cycle. Pfcyc-1
appears as a 37-kDa band (in good agreement with the calcu-
lated molecular mass of 39.2 kDa) whose abundance peaks in
FIG. 3. Western blot analysis. A, specificity of the immunopurified anti-Pfcyc-1, -2, and -4 antibodies. Membranes carrying recombinant
GST-Pfcyc-1, GST-Pfcyc-2, and GST-Pfcyc4/CB were probed with the antibodies indicated above. This demonstrates the absence of cross-reactivity
of these antibodies with the noncognate cyclins. B, Western blot analysis of stage specific P. falciparum extracts. 20 g of synchronized stage
specific extracts obtained at 6-h intervals starting from 18 h post-sorbitol treatment were resolved in 12% SDS-polyacrylamide gels. Mouse PfPK5
(1:500) antibody and chicken Pfcyc-1 (1:750), Pfcyc-2 (1:2,000), and Pfcyc-4 (1:10,000) antibodies were used with appropriate secondary antibodies.
A representative parasite infected erythrocyte from each time point is shown in the top panel. Lanes 1–3, trophozoite; lanes 4 and 5, schizont; lanes
6 and 7, ring. C, quantification of the Western blot signals. The densitometric value of each band was normalized against the total amount of
protein in each lane, as determined by Coomassie staining/densitometric measurement of two gels loaded with identical volumes of each extract.
The relative intensities are given as the ratios to the value of the relevant band in lane 1. For comparative purposes, the values for PfPK5 are given
in relation to those for the three cyclins.















mature trophozoites, like PfPK5; the lower band visible on the
Western blot follows a similar distribution and may represent
a degradation product. The calculated molecular mass of Pf-
cyc-2 is 276.1 kDa. Accordingly, the Pfcyc-2 antibody reveals a
set of large bands (50 to 250 kDa) present predominantly in
segmenters, although some of these are visible throughout the
cycle. Interestingly, the most prominent band detected with the
Pfcyc-2 antibody has an apparent size of 30 kDa and peaks in
trophozoites. Whether or not this band arises from proteolytic
cleavage from the large Pfcyc-2 polypeptide remains to be es-
tablished (see “Discussion”). The antibody against Pfcyc-4 (cal-
culated molecular mass, 31.1 kDa) yields two major bands with
distinct expression patterns: a 31-kDa band peaks in tropho-
zoites and a 39-kDa species that clearly shows maximum ex-
pression in segmenters, with high levels maintained in rings.
As is the case for Pfcyc-2, the Pfcyc-4 antibody also detects high
molecular weight bands (see “Discussion”). Competition exper-
iments with the Pfcyc-2 and Pfcyc-4 antibodies (not shown)
demonstrated that incubation of the antibodies with the rele-
vant peptides abolished the Western blot signals.
Association of Recombinant Pfcyc-1 and Pfcyc-4 with
Histone H1 Kinase Activity
We next wanted to investigate the biochemical properties of
the proteins encoded by the Pfcyc genes, especially with respect
to their potential association with kinase activity. To this end,
we expressed all four proteins (Pfcyc-1 to Pfcyc-4) in E. coli. The
entire coding regions of Pfcyc-1 and Pfcyc-3 were cloned into
pGEX vectors to generate GST-cyclin fusion proteins; for the
Pfcyc-2 ORF, of which only a small region is related to cyclins,
we chose to express only the region between residues 986 and
1376, which spans the cyclin-like region. Two constructs were
made for Pfcyc-4: the first one (Pfcyc-4/NT) encoded the 74
N-terminal residues (i.e. as found in our first data base search;
see above) fused to GST. After identifying a larger Pfcyc-4 ORF
in PlasmoDB, we prepared another plasmid (Pfcyc-4/CB) con-
taining the entire predicted coding region (carrying a frame-
shift deletion at residue 565 and therefore expressing only one
full cyclin box) (see above and Fig. 1C). Expression was suc-
cessful for Pfcyc-1, Pfcyc-2, Pfcyc-4/CB, and Pfcyc-4/NT; how-
ever, we were unable to express Pfcyc-3 as a GST fusion pro-
tein. We therefore switched to the expression system
generating a fusion with the maltose-binding protein (MBP).
This somewhat improved the yield, but the total amount ob-
tained was not sufficient to perform pull-down experiments
with this particular protein.
We performed pull-down experiments to determine whether
the recombinant cyclin-related molecules were able to associate
with a kinase activity in parasite extracts. Glutathione-agarose
beads were coated with similar amounts of either GST alone (as
a negative control), GST-Pfcyc-1, GST-Pfcyc-2, GST-Pfcyc-4/
NT, or GST-Pfcyc-4/CB. The beads were then incubated in
either parasite extract (asynchronous asexual stages) or para-
site lysis buffer alone (without parasite material) and washed.
The material bound to the beads was subsequently assayed for
histone H1 kinase activity (Fig. 4). No such activity was detect-
able in any sample that had not been in contact with the
parasite protein extract (lanes 6–9), indicating that the H1
kinase activity is not of bacterial origin. In those samples that
had been incubated in parasite extract, a weak signal, presum-
ably originating from nonspecific binding of protein kinases to
the beads, was present in the “GST alone” negative control (not
shown). A signal of identical intensity was observed on the
beads coated with GST-Pfcyc-2 (lane 3), indicating that this
particular recombinant protein did not associate specifically
with a kinase activity under these conditions (and, inciden-
tally, provides a valuable additional negative control). In con-
trast, a strong signal was detected when the beads had been
coated with Pfcyc-1 (lane 2) and Pfcyc-4 (lanes 4 and 5). In the
latter case, the recombinant protein containing only the 74
N-terminal residues of Pfcyc-4 was as efficient as the protein
containing a entire cyclin box to pull down the kinase activity
(compare lanes 4 and 5). These data strongly suggest that the
proteins encoded by the Pfcyc-1 and Pfcyc-4 genes are able to
bind to a protein kinase present in the parasite extract and are
consistent with the in vitro cyclin activity that we reported
previously for Pfcyc-1 (10).
Immunoprecipitation of Histone H1 Kinase Activity
Using Antibodies against Four P. falciparum
Cylin-related Proteins
The ability of the malarial cyclin-related proteins to associ-
ate with a kinase activity from parasite extracts was also
investigated by immunoprecipitation of the native proteins in
parasite extracts using the monospecific, immunopurified an-
tibodies described above (Fig. 5). This allowed us to test a
possible association of Pfcyc-3 (which was not produced in
sufficient amounts in E. coli to allow us to perform the
pull-down experiment described above) with kinase activity
in parasite extracts. Immunoprecipitates obtained with Pf-
cyc-1 and Pfcyc-4 antibodies contained a high level of histone
kinase activity (lanes 2 and 5), thereby independently con-
firming the pull-down data. Immunoprecipitated Pfcyc-2 and
FIG. 4. Pull-down experiment using recombinant cyclins, cou-
pled to kinase assays. GST-Pfcyc-1 (lanes 2 and 6), GST-Pfcyc-2
(lanes 3 and 7), GST-Pfcyc-4/NT (lanes 4 and 8), and GST-Pfcyc-4/CB
(lanes 5 and 9) were incubated either in parasite extract (lanes 2–5) or
in parasite lysis buffer without parasite material (lanes 6–9). The beads
were washed, and bound material was assayed for Histone H1 kinase
activity. The kinase reactions were then run on a polyacrylamide gel
that was subjected to autoradiography. Lane 1 shows the background
signal of a kinase assay (histone H1 only, without any malarial recom-
binant protein or extract).
FIG. 5. Immunoprecipitations from parasite extracts using an-
ti-cyclin antibodies, coupled to kinase assays. Immunopurified
chicken IgY antibodies against peptides from Pfcyc-1 (lanes 2 and 10),
Pfcyc-2 (lanes 3 and 11), Pfcyc-3 (lanes 4 and 12), and Pfcyc-4 (lanes 5
and 13) were incubated in parasite extracts (lanes 2–9) or parasite lysis
buffer without parasite material (lanes 10–16). Negative controls con-
sisted of nonimmune unpurified IgYs (lanes 6 and 14), immunopurified
IgY antibodies against the C5a receptor (lanes 7 and 15) or MIE-2 (lanes
8 and 15), and immunoprecipitation performed in the absence of IgY
antibodies (secondary anti-chicken IgY antibodies only) (see “Experi-
mental Procedures”). Immune complexes were pelleted using protein
A-agarose beads coated with rabbit anti-IgY secondary antibodies. The
beads were washed, and bound material was assayed for Histone H1
kinase activity. The kinase reactions were then run on a polyacrylamide
gel, which was subjected to autoradiography. Lane 1 shows the back-

















Pfcyc-3 (lanes 3 and 4, respectively) also gave signals that
were repeatedly higher than background (lanes 6 and 7),
albeit to a lesser extent than Pfcyc-1 and Pfcyc-4. This sug-
gests that all four cyclin-related proteins associate with his-
tone H1 kinase activity present in the parasite extract (see
“Discussion”).
Activation of PfPK5 by Recombinant Pfcyc-3
We demonstrated earlier that PfPK5, the malarial protein
kinase that is most closely related to CDK1, displays a relaxed
specificity with respect to the cyclins that can activate it in
vitro (10). We therefore tested the ability of the three novel
recombinant cyclin-related proteins to activate His-tagged
PfPK5. GST-Pfcyc-1 used as a positive control repeatedly had
the previously described (10) ability to stimulate PfPK5, using
as substrates either histone H1 or the C-terminal domain
(CTD) of RNA polymerase II. GST-Pfcyc-2 never displayed any
significant PfPK5-activating activity in this series of experi-
ments, whereas some batches of GST-Pfcyc-4 displayed mar-
ginal levels of activity (data not shown). In contrast, MBP-
Pfcyc-3 stimulated PfPK5 activity against the CTD in a dose-
dependent manner, whereas the MBP moiety alone showed no
effect (Fig. 6A). The level of PfPK5 activation by MBP-Pfcyc-3
was heavily dependent on the batches of recombinant proteins,
with some preparations lacking activity altogether. MBP-Pf-
cyc-3 was poorly expressed in E. coli, and the amounts of
protein obtained were in general too low to allow quantification
of the full-length fusion protein prior to performing the kinase
assay (this explains why the amount of MBP-Pfcyc-3 used in
these experiments is expressed in the figure legend as the
volume of purified protein rather than as the mass of recombi-
nant protein). Therefore, it appears that the “specific activity”
of MBP-Pfcyc-3 in this assay was relatively high compared with
that of GST-Pfcyc-1 (which was routinely used in microgram
amounts).
An unexpected property of PfPK5 was its ability to autophos-
phorylate in the presence of GST-Pfcyc-1 (10). To determine
FIG. 6. Stimulation of recombinant PfPK5 by recombinant Pf-
cyc-3. A, dose dependence. Kinase assays were performed using 2 g of
GST-CTD as a substrate, with 1.0 g of His-PfPK5 and the following
volumes of an MBP-Pfcyc-3 preparation: lane 2, no MBP-Pfcyc-3; lane 3,
0.4 l; lane 4, 0.8 l; lane 5, 1.6 l; lane 6, 3.2 l. The reactions for lanes
6–8 contained no MBP-Pfcyc-3 but 0.6 g (0.4 l), 1.2 g (0.8 l), and
4.8 g (2.0 l) MBP moiety alone, respectively. Lane 1 shows the
background signal of a kinase assay (GST-CTD only, without any other
recombinant protein). B, PfPK5 autophosphorylation in the presence of
GST-Pfcyc-1 but not in the presence of MBP-Pfcyc-3. Kinase assays
were performed with the following proteins: lane 1, 1.0 g of His-PfPK5
and GST-CTD; lane 2, GST-CTD; lane 3, GST-CTD, His-PfPK5, and
MBP-Pfcyc-3 (1 l); lane 4, GST-CTD, His-PfPK5, 1 g of GST-Pfcyc-1;
lane 5, His-PfPK5, GST-Pfcyc-1; lane 6, His-PfPK5 and MBP-Pfcyc-3;
lane 7, GST-Pfcyc-1 and GST-CTD; lane 8, MBP-Pfcyc-3 and GST-CTD.
The kinase reactions were then run on a polyacrylamide gel that was
subjected to autoradiography.
FIG. 7. Stimulation of PfPK5 activity by recombinant RINGO
protein. A, dose dependence. Inset, kinase assays were performed with
1 g of recombinant (His-tagged) PfPK5 and the following amounts of
MBP-RINGO: lane 3, 5 ng; lane 4, 10 ng; lane 5, 25 ng; lane 6, 50 ng;
lane 7, 75 ng; lane 8, 100 ng; lane 9, 125 ng; lane 10, 250 ng. Lane 1 is
histone substrate alone (5 g) (no PfPK5), and lane 2 shows the basal
activity of PfPK5 (in the absence of RINGO). To obtain a graphical
representation, similar reactions as those described above were per-
formed and the reaction mixtures were spotted on P81 paper for quan-
tification (see “Experimental Procedures”). Each point represents an
average value from two different experiments, each done in duplicate.
The standard deviation is indicated. B, possible PfPK5 autophospho-
rylation in the presence of MBP-RINGO. Kinase assays were performed
with the following proteins: lane 1, 5 g of histone H1; lane 2, RINGO
(0.25 g) and histone H1; lane 3, His-PfPK5 (0.5 g) and histone H1;
lane 4, His-PfPK5 and RINGO; lane 5, His-PfPK5, RINGO and histone
H1. The kinase reactions were then run on a polyacrylamide gel that
was subjected to autoradiography. C, comparative efficiency of MBP-
RINGO and GST-Pfcyc-1 for activation of His-PfPK5. PfPK5 (50 ng)
kinase assays were performed with the following recombinant proteins,
using histone H1 as a substrate: lane 1, 250 ng of MBP-RINGO; lane 2,
100 ng of MBP-RINGO; lane 3, 50 ng of MBP-RINGO; lane 4, no
activator protein; lane 5, 1 g of GST-Pfcyc-1. Lane 6 is the negative
control (reaction with histone H1 but no recombinant proteins). After
electrophoresis, the gel was autoradiographed for 30 min.















whether the enzyme would also display this property in the
presence of MBP-Pfcyc-3, we performed kinase assays using
both recombinant cyclins in such conditions as to obtain a
similar level of PfPK5 activity toward CTD (Fig. 6B, compare
lanes 3 and 4). It is clear that PfPK5 autophosphorylates in the
presence of Pfcyc-1 (lanes 4 and 5) but not in the presence of
Pfcyc-3 (lane 3 and 6).
Activation of PfPK5 by RINGO
The in silico searches that lead to the identification of Pfcyc-1
to Pfcyc-4 were based solely on homology to cyclins. However,
in other systems there are examples of CDKs being activated
by proteins that show no obvious sequence homology to cyclins.
For example, mammalian p25, an activator of CDK5 with no
relatedness to cyclins at the primary structure level, is very
similar to cyclins in its tri-dimensional structure because it
shares the so-called “cyclin fold”; we demonstrated earlier that
p25 is an efficient activator of PfPK5 (10). Another “noncyclin”
activator of CDK1 and CDK2, RINGO, has more recently been
described (13, 14). As shown in Fig. 7, RINGO is an efficient
activator of PfPK5. The addition of increasing amounts of re-
combinant RINGO (from 0 to 250 ng) to a fixed amount of
PfPK5 (1 g) resulted in a linear increase in kinase activity
(Fig. 7A, lanes 2–10). With larger amounts of RINGO, a plateau
effect was observed, as expected (data not shown). Obviously,
we verified (i) that the preparations of MBP-RINGO used for
these experiments did not carry any intrinsic kinase activity
and (ii) that the MBP moiety alone has no effect on PfPK5
activity (data not shown, but see Fig. 6A, lanes 7–9). As is the
case with Pfcyc-1 but not Pfcyc-3 (Fig. 6B), PfPK5 appears to
undergo autophosphorylation in the presence of RINGO (Fig.
7B, lane 4); however, because the RINGO protein itself is
efficiently phosphorylated by PfPK5 (Fig. 7B, lanes 4 and 5), we
cannot at this stage exclude that the band observed at 34 kDa
in Fig. 7B is a RINGO degradation product rather than phos-
phorylated PfPK5. Although it is difficult to accurately quan-
tify the stimulatory effect of the various activators on PfPK5
because of the very low level of basal activity of the kinase,
RINGO clearly appears to be a stronger activator of the malar-
ial CDK than other recombinant proteins (such as Pfcyc-1)
tested at similar concentrations; 20-fold more GST-Pfcyc-1
than MBP-RINGO was needed to generate a similar signal
from a fixed amount of PfPK5 (Fig. 7C). This is in agreement
with our independent estimations of a PfPK5 activation factor
of up to 3 orders of magnitude by GST-Pfcyc-1 (10) and of more
than 4 orders of magnitude by MBP-RINGO (this study and
data not shown).
DISCUSSION
Identification of Three Novel Potential Cell Cycle Regula-
tors in Malaria Parasites—Plasmodium post-genomics is
coming of age, and the availability of sequence data bases for
several species of malaria parasites has revolutionized the
study of the molecular biology of this important genus of
pathogenic organisms. An obvious benefit of this recent de-
velopment is the ease with which putative homologues of
gene products of interest (notably with respect to potential
drug or vaccine targets) can be identified, cloned, and char-
acterized (25). Here we report the identification and prelim-
inary characterization of three genes encoding novel putative
P. falciparum cell cycle regulators.
The purpose of this study was to identify P. falciparum
regulators of cyclin-dependent kinases. In addition to Pfcyc-1
(10), searches of the P. falciparum genomic data base has
revealed three additional cyclin-related proteins, all of which
appear to be expressed in blood stages of the infection. The
three different molecules for which Western blot analysis was
possible, Pfcyc-1, Pfcyc-2, and Pfcyc-4, have characteristic pat-
terns of expression, which may indicate that they have distinct
and nonredundant roles in the malaria cell cycle. For example,
the 30-kDa form of Pfcyc-4 is present in high levels in segment-
ers and in rings but in lower levels in trophozoites, in marked
contrast with Pfcyc-1, which peaks in trophozoites, similar to
PfPK5, a P. falciparum CDK1 putative homologue (8). Further-
more, these molecules appear to undergo differential process-
ing and/or degradation processes. Differential splicing modifi-
cations cannot be ruled out as a possible explanation for the
presence of some of the observed protein species. Indeed, each
of the cyclin genes identified in the present study would war-
rant a detailed study of the structure of its mRNA(s) and of the
post-translational modifications its products undergo during
the life cycle of the parasite.
Biochemical Properties of the Novel Plasmodium Cyclins—
The products of Pfcyc-1, Pfcyc-3, and Pfcyc-4 possess functional
properties consistent with their belonging to the cyclin family,
i.e. association with histone H1 kinase activity present in par-
asite extracts (Pfcyc-4; see Figs. 4 and 5) or direct activation of
PfPK5 in vitro (Pfcyc-3; see Fig. 6). Although all of the Pfcyc-4
amplicons we obtained from cDNA encoded only one of the two
cyclin boxes because of a frameshift deletion (Fig. 1C), the
recombinant protein was able to associate to a kinase activity.
Furthermore, a short region of Pfcyc-4 (the 75 N-terminal res-
idues) is sufficient to display this kinase-binding activity. This
study also shows that Pfcyc-1, for which available functional
data were thus far restricted to the demonstration of PfPK5
activation in vitro, associates with a histone kinase activity in
parasite extracts. In contrast, the recombinant cyclin-like do-
main contained within the (much larger) Pfcyc-2 ORF was
unable to pull down a kinase activity from parasite extracts,
although immunoprecipitates from such extracts obtained by
using a mono-specific anti-Pfcyc-2 antibody contained levels of
histone H1 kinase activity that were significantly above back-
ground. A possible explanation for this apparent discrepancy is
that the domain expressed in recombinant Pfcyc-2 may lack
regions that are essential for interaction with the kinase sub-
unit. An alternative possibility is that the cognate catalytic
subunit (see below), or an additional required factor, was not
present in sufficient amounts in the free, unbound form in the
parasite extracts to allow detection under these conditions.
Although the immunoprecipitation data are consistent with a
cyclin function for Pfcyc-2, we cannot formally exclude at this
stage that they arose from cross-reactivity of the antibody to a
different protein present in the parasite extract; although the
immunopurified anti-Pfcyc-2 antibody does not show any cross-
reactivity with recombinant Pfcyc-1 or Pfcyc-4 (Fig. 3A), cross-
reactivity with another as yet unidentified protein with cyclin-
like activity is possible (albeit unlikely). A scan of the entire
P. falciparum genome with the sequences of the peptides used
for immunization showed that these sequences are indeed
unique and that no closely related sequences are found in
PlasmoDB.
Notwithstanding Pfcyc-2, the present study brings to three
the number of parasite proteins with demonstrated cyclin prop-
erties (Pfcyc-1, Pfcyc-3, and Pfcyc-4). Their identity was uncov-
ered on the basis of overall homology levels, but none of these
sequences possess specific motifs found in cyclins in other sys-
tems. For example, the MRAIL motif, which in many cyclins
mediates interactions with the RXL motif present in substrates
or regulators (26, 27), is not present in the plasmodial mole-
cules. The “destruction box” targeting proteins (including many
cyclins) for ubiquitin-dependent proteolysis (28, 29) is also ap-
parently missing. In this respect, it is worth mentioning that
















whether or not it is used to regulate cyclin levels remains to be
investigated. In particular, it would be of interest to determine
whether some of the high molecular mass bands observed on
Western blots (Fig. 3) may be polyubiquitinated forms of the
proteins.
We identified Pfcyc-3 as yet another cyclin (and the second
one from P. falciparum, the first one being Pfcyc-1) able to
activate PfPK5 in vitro, confirming the promiscuity of this
kinase with respect to its activating partners. Obviously, the
relevance of this finding remains to be established in an in vivo
context. Interestingly, Pfcyc-1 and Pfcyc-3 have differential
effects on PfPK5; in conditions where both cyclins activate the
kinase to a similar level toward an exogenous substrate (Fig.
6B), it is only in the presence of Pfcyc-1 that autophosphoryl-
ation occurs (the nonplasmodial activator RINGO seems to
behave like Pfcyc-1 in this respect (Fig. 7B)). Autophosphoryl-
ation has to our knowledge not been documented in CDKs from
other systems, even in vitro. The identity of the target residue
and whether or not this phenomenon has any physiological
relevance remain to be determined. It is still not clear whether
or not P. falciparum possesses a CAK; Pfmrk, a kinase with
maximal homology to the mammalian CAK CDK7, can be ac-
tivated in vitro by Pfcyc-1 and by mammalian cyclin H to
phosphorylate histone H1 but does not appear to use PfPK5 as
a substrate in these conditions (10). The observation that
RINGO, which activates mammalian CDKs in a CAK-inde-
pendent manner (14), is a powerful activator of PfPK5 may
suggest that this enzyme may be regulated in a similar (CAK-
independent) way in vivo.
Cryptic Cell Cycle Regulators in the P. falciparum Ge-
nome?—In eukaryotic systems where cell cycle control is better
understood, the number of cyclins is generally larger than that
of catalytic subunits, and in several instances a given catalytic
subunit can be activated by a number of different cyclins, each
of which confers different catalytic properties (e.g. in terms of
substrate specificity) to the kinase subunit (31, 32). A superfi-
cial examination of the P. falciparum genome CDK and cyclin
content, based on sequence homology, seems to suggest that
the number of cyclins is surprisingly small. However, the ob-
servation that RINGO (this study) and p25 (10), two proteins
with no homology to cyclins at the primary structure level, are
efficient activators of a malarial CDK, together with the fact
that 50% of the ORFs in the Plasmodium genome are not
related to any known protein (3), leaves open the possibility
that “cryptic” cyclin functional homologues may be present in
Plasmodium. It is relevant to mention here that no obvious
homologues of RINGO or p25 have yet been identified in
PlasmoDB.
Reconstructing the Plasmodium Cell Cycle Control Net-
work—A possible avenue to overcome the problem of identifi-
cation of cryptic CDK regulators is to exploit genomic data
bases in a mass spectrometry-based approach, in which pro-
teins interacting with a given tagged CDK (or cyclin) can be
purified from parasite extracts by affinity chromatography and
hydrolyzed into peptides. They can then be subjected to mass
spectrometry analysis and identified against genomic data
bases (33, 34). This should allow us not only to identify novel
(possibly cryptic) functional homologues of cell cycle regulators
but also to determine which already characterized molecules
form cognate CDK-cyclin pairs. This presents a particular in-
terest in the context of investigations into regulatory networks
of such a phylogentically isolated group of organisms as the
Apicomplexa, where the precise function of proteins often can-
not be predicted from sequence alone. For example, one would
not have predicted that PfPK5, a putative CDK1 homologue,
would be activated by Pfcyc-1, a protein that is most closely
related, at the primary structure level, to the cyclin H family
and would therefore be expected to specifically activate a CDK7
homologue (for an extended discussion of this topic, see Ref. 5).
Two of the cyclins described here clearly display primary struc-
ture relatedness to well defined classes of cyclins, as deter-
mined by BLAST analysis; the Pfcyc-2 sequence is more related
to mitotic (A and B) cyclins (despite lacking a MRAIL motif; see
above and Fig. 1A), and Pfcyc-4 appears to fall within the
ania-6 family of cyclins (22). Members of the latter family
appear to play a role in transcription control in some mamma-
lian cell types and have been show to associate with CDK-
related kinases of the PITSLRE family (22). Several isoforms of
PITSLRE kinases are found in mammalian cells and play a role
in a variety of processes, including cell division (35) and tran-
scriptional control (36). Pfcrk-1 is a putative malarial mem-
ber of this kinase family (37), and it would be tempting to
speculate that Pfcyc-4 may be an activating partner for this
enzyme. However, in view of the unexpected observations
(discussed above) concerning the cyclins capable of activating
PfPK5 and considering the well known limitations of BLAST
analysis-based protein classification (38), it would be danger-
ous to predict precise functions (and/or kinase subunit part-
ners) for the cyclins described in this work on the sole basis
of their sequence. Clearly, the functions of these elements
must be explored experimentally. To this end, we envisage
adopting the RNA interference approach, which has recently
been applied successfully to essential plasmodial genes
(39–41).
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